Scientists have injected a human medical trial participant with a cancer-killing virus known as Vaxinia that is designed to kill cancer cells.
The City of Hope, one of the largest cancer treatment and research organizations in the United States of America, announced in a press release that it had begun Phase 1 of its clinical trial to use a modified virus to target advanced solid tumors.
According to scientists, the first human patient has been injected with Vaxinia, a “revolutionary” cancer-killing virus that has previously been successfully employed on animals.
The researchers expect that the virus will boost the body’s immune system response, allowing it to better combat cancer cells. The drug has shown to be effective in shrinking colon, lung, breast, ovarian, and pancreatic tumors,
Vaxinia was created to kill cancer cells and has shown encouraging results in animal testing.
The researchers ensured that the virus was not only cancer-killing, but also able to make it more recognized to the immune system in this current trial.
In Phase 1, the vaccination is being studied on 100 patients with a metastatic or advanced solid tumor who have already tried at least two different treatments.
The medicine will be given to two groups: one will receive Vaxinia, while the other will receive the cancer-killing virus along with an immunotherapy drug.
Phase 1 is primarily concerned with maintaining safety and establishing the proper dose, therefore they do not provide the intended outcomes right away.
When scientists tested the virus on animals, it was able to decrease the tumor in the studies, which was a huge success. While a successful animal experiment does not guarantee a positive outcome in human trials, experts are hoping that this will open up new avenues for the body to fight cancer. By 2025, the study is projected to be completed.